Interaction between Pilocarpine and Alectinib
Moderate Synergy

ID DDInter1465 and DDInter39
Interaction Coadministration of alectinib with other agents that can slow the heart rate may increase the risk of bradycardia.
Management Caution is advised when alectinib is prescribed with other drugs that can cause bradycardia (e.g., beta-blockers; calcium channel blockers; digitalis; dolasetron; flecainide; ivabradine; lacosamide; mefloquine; moricizine; propafenone; quinine; succinylcholine; sunitinib; thalidomide; anticholinesterase or cholinergic agents; protease inhibitors such as atazanavir, lopinavir/ritonavir, and saquinavir/ritonavir). Heart rate and blood pressure should be monitored regularly, and patients should be counseled to seek medical attention if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.
References
Alternative for Pilocarpine N07A
Pilocarpine (ophthalmic)
Bethanechol
Carbamoylcholine (ophthalmic)

S01E
Brinzolamide (ophthalmic)
Brimonidine (topical)
Carbamoylcholine (ophthalmic)
Epinephrine (topical)
Epinephrine
Tafluprost (ophthalmic)
Dipivefrin (ophthalmic)
Dorzolamide (ophthalmic)
More
Alternative for Alectinib L01X
Glasdegib
Aminolevulinic acid
Vismodegib
Regorafenib
Fedratinib
Olaparib
Bortezomib
Panobinostat
Cemiplimab
Estramustine
Ipilimumab
More

Potential Metabolism Interactions

Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.